Yanshuo Cao

Yanshuo Cao

Auto-generated profile, based on publicly available information

Yanshuo Cao

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Department of GI Oncology, Peking University Cancer Hospital & Institute, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CQChangsong Qi
Changsong Qi
CLChang Liu
Chang Liu
JGJifang Gong
Jifang Gong
DLDan Liu
Dan Liu
XWXicheng Wang
Xicheng Wang
SLShen Lin
Shen Lin

10 July 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CLChang Liu
Chang Liu
DLDan Liu
Dan Liu
YJYinghua Ji
Yinghua Ji
MSMeili Sun
Meili Sun
SGShegan Gao
Shegan Gao
ZLZhihao Lu
Zhihao Lu
Research on patients with advanced esophageal squamous cell carcinoma (ESCC) who have progressed on immunotherapy remains limited. BL-B01D1 is a first-in-class antibody–drug conjugate consisting of an EGFR–HER3 bispecific antibody bound to a topoisomerase I inhibitor (Ed-04) payload via a cleavable linker. Here, we present safety and efficacy data from a phase 1 study of BL-B01D1, in 82 patients previously treated for ESCC. The primary endpoint was the recommended phase 2 dose. Administered doses were 2.0 (n = 22) and 2.5 (n = 60) mg kg−1 D1D8 infusion every 3 weeks (Q3W). The confirmed objective response rate (cORR) was 29.3% (24 of 82) in all patients and 32.9% (24 of 73) among evaluable patients. For patients dosed at 2.5 mg kg−1, cORR was 39.6% (21 of 53) and disease control rate was 79.2% (42 of 53). In the 2.0 mg kg−1 group, cORR was 15.0% (3 of 20), and the disease control rate was 50.0% (10 of 20). The phase 2 dose was established at 2.5 mg kg−1 D1D8 Q3W. The incidence of G3 treatment-related adverse events at 2.5 mg kg−1 was 63.3%; most common adverse events were anemia (28.3%), leukopenia and thrombocytopenia (18.3%, each), and neutropenia (16.7%). Two cases of ≥G3 interstitial lung disease were observed. Overall, BL-B01D1 demonstrated promising efficacy and manageable safety in patients with metastatic ESCC. A further phase 3 clinical trial has already been initiated. ClinicalTrials.gov registration: NCT05262491.

23 November 2020 in Cancer Communications
Verified
Journal Article
Open access
PDF file
YCYanshuo Cao
Yanshuo Cao
YMYutong Ma
Yutong Ma
JYJiangyuan Yu
Jiangyuan Yu
YSYu Sun
Yu Sun
TSTingting Sun
Tingting Sun
MLMing Lu
Ming Lu
Neuroendocrine neoplasm of the pancreas is a rare tumor with limited treatment options. Among such tumors, treatment for pancreatic neuroendocrine tumor (PanNET) G3 is the most difficult. Temozolomide (TMZ) is commonly used to treat PanNET. However, TMZ may cause tumor gene alkylation, which induces drug resistance and rapid disease progression. Herein, we present a case of a female who was diagnosed with PanNET G3 and achieved a partial response to toripalimab, an anti‐programmed cell death‐ligand 1 (anti‐PD‐L1) monoclonal antibody, after multiple cycles of TMZ treatment. Genomic profiling revealed that compared with the patient's samples collected at baseline, the post‐TMZ‐treatment samples had markedly higher levels of tumor mutational burden (TMB) associated with characteristic alkylating mutational signature representing a positive correlation with favorable response to anti‐PD‐1 treatment. In addition, we observed a germline truncating mutation of MUTYH (W156*) that was considered to be pathogenic and potentially conferred to genomic instability. This case suggests that anti‐PD‐1 therapy could be a treatment option for PanNET patients with increased TMB after TMZ‐based treatment.


30 September 2021 in Neuroendocrinology
Verified
Journal Article
Open access
PDF file
JZJianwei Zhang
Jianwei Zhang
YCYanshuo Cao
Yanshuo Cao
PZPanpan Zhang
Panpan Zhang
XZXiaotian Zhang
Xiaotian Zhang
JLJian Li
Jian Li
MLMing Lu
Ming Lu
Objective: Gastroenteropancreatic neuroendocrine carcinoma (GEPNEC) is a major research focus, but the application of biomarkers to guide its prognostication and management is unsatisfying. Clinical values of conventional serum biomarkers, neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA199) warrant scrutiny. Methods: Patients diagnosed with GEPNEC with baseline NSE, CEA, and CA199 levels provided in Peking University Cancer Hospital were retrospectively studied. Relationships between biomarkers and prognosis were investigated by the χ2 test, Kaplan-Meier analysis, and univariate and multivariate Cox regression analyses. Results: A total of 640 GEPNEC patients were enrolled. NSE, CEA, and CA199 were elevated in 59.5%, 28.5%, and 21.3% of the population, respectively. Higher NSE had worse median overall survival (OS) (17.0 months vs. not reached, hazard ratio = 2.77 [2.06, 3.73], p < 0.001), and so did patients with higher CEA and CA199. Multivariable analysis confirmed that NSE and CA199 correlated with OS independently. Baseline NSE level and NSE remission predicted OS and the response of patients with first-line etoposide plus cisplatin (EP) treatment. Furthermore, we combined NSE/CEA/CA199 to segregate GEPNEC into novel subgroups, namely, adenocarcinoma-like NEC (ALN), neuroendocrine-like NEC (NLN), and triple-normal NEC (TNN). The groups shared distinctive clinicopathologic features and prognosis (21.0 months vs. 17.1 months vs. not reached, p < 0.001). The EP regimen remained the priority treatment option in NLN/TNN, while ALN was predisposed to “adenocarcinoma-like chemotherapy.” Conclusions: Elevation of NSE, CEA, or CA199 was common and independently indicates poor prognosis in GEPNEC patients. Serum biomarker-based subtypes suggest meaningful clinical implications and appropriate therapeutic approaches, illuminating promising ways to characterize the prognosis of GEPNEC.

12 June 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
ZJZhao Jin
Zhao Jin
YCYanshuo Cao
Yanshuo Cao
ZLZhihao Lu
Zhihao Lu
CLChang Liu
Chang Liu
SLShen Lin
Shen Lin